All News
Although there is a bidirectional relationship betw pain and sleep, Sleep impairment more strongly predicts pain than pain does sleep. Addressing sleep disturbances is crucial, as it is linked to higher levels of disability, depression, pain-related catastrophizing.… https://t.co/pcFeCWSBCg https://t.co/0QlnbpKEbp
Dr. John Cush RheumNow ( View Tweet)
CorEvitas registry study of 1823 psoriatic arthritis pts found that 11.1% fulfilled the fibromyalgia definition and 20.6% fulfilled the widespread pain definition. Factors assoc w/ FM: female, depression, anxiety, impaired function, BMI & #of comorbidities.… https://t.co/nDk8hPTlAu https://t.co/jnO5MijoGJ
Dr. John Cush RheumNow ( View Tweet)
54K Peptic Ulcers Annually (12.13.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com
Read Article
CorEvitas registry study of 1823 psoriatic arthritis pts found that 11.1% fulfilled the fibromyalgia definition and 20.6% fulfilled the widespread pain definition. Factors assoc w/ FM: female, depression, anxiety, impaired function, BMI & #of comorbidities.… https://t.co/rBZwUxQ8yw https://t.co/W42YDBnDCa
Dr. John Cush RheumNow ( View Tweet)
Why should rheumatologists care about aging?
The global population is aging and none of our rheumatic diseases are immune to the impact of the complexities and so-called “geriatric syndromes”, including sarcopenia, frailty, falls and cognitive impairment, associated with the aging process. Whilst we are increasingly aware of these syndromes, it is sometimes overwhelming to consider just how we may incorporate the unique needs of our older patients into our already busy clinical practice – or perhaps until now we were unsure of their significance and relevance. Why should we care about aging?
Read Article
Cognitive Impairment: The Hidden Burden in Lupus Care
Suppose you have a patient with SLE returning for follow-up. Their joint symptoms are well controlled. The kidneys—managed with a combination of biologic DMARD and mycophenolate—show no signs of active urinary sediment or… https://t.co/W8RO5aOaxj https://t.co/EF9P93hdPB
Dr. John Cush RheumNow ( View Tweet)
Cognitive Impairment: The Hidden Burden in Lupus Care
Suppose you have a patient with lupus returning for follow-up. Their joint symptoms are well controlled. The kidneys—managed with a combination of biologic DMARD and mycophenolate—show no signs of active urinary sediment or protein. Yet, during the routine visit, your patient brings up fatigue and difficulty remembering things. How do you address this? Several studies presented at ACR24 focused on cognitive impairment in lupus.
Read Article
axSpA: Moving the needle in time to diagnosis
The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging. Understanding the factors contributing to the delays is important to improve the clinical, psychological, social and economic outcomes.… https://t.co/wnwtj8jj0q https://t.co/Pds2uxVfJV
Dr. John Cush RheumNow ( View Tweet)
If your pt with #rheumatoid #arthritis is
#exhausted - there is a reason
#Meta-analysis of 70000 RA Pts
#Insomnia is ⬆️4X vs gen population
Due to
▶️#pain
▶️#inflammation
▶️#depression
🤷♀️
#ACR24 @RheumNow @ACRheum abst#0480
Janet Pope Janetbirdope ( View Tweet)
Pathophysiological pathways in neuropsychiatric SLE. 2 components:
-Ischaemic
-Inflammatory
Zahi Touma @RheumNow #ACR24 https://t.co/wwlSSSpOIU
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
How often do you ask about #fatigue, #depression & #anxiety in pts with RMDs?
Study of >1000 pts found anxiety symptoms in 1/3 pts and significant association between fatigue & anxiety and depression
Highlights importance of regular review of MH symptoms
Ab2657 #ACR24 @RheumNow https://t.co/0zMOMybrCI
Mrinalini Dey DrMiniDey ( View Tweet)
Neuropsychiatric manifestations in SLE.
Susanne Benseler MD @RheumNow #ACR24 https://t.co/subiykC5Q4
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Neuroimaging is done to support the diagnosis of CNS #lupus but only 75% reveal abnormal brain MRI.
📌 It is more useful in pts with local deficits than diffuse.
📌 poorly correlated with cognitive dysfunction & psych phenotypes.
@Rheumnow #ACR24 @rheumarhyme @theactiverheum https://t.co/HjNbVBaOHv
sheila RHEUMarampa ( View Tweet)
The different NPSLE syndromes 👇
Highlighted in yellow are the most common manifestations. 🧠
- Cognitive dysfunction
- Mood disorder
- Anxiety disorder
@RheumNow #ACR24 https://t.co/1I7OVPT6DK
sheila RHEUMarampa ( View Tweet)
Diagnostic work up for neuropsychiatric SLE. Zahi Touma MD @RheumNow #ACR24 https://t.co/zLX1QHCaSu
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Mental health, sex, and comorbidities are key factors in determining recalcitrant psoriatic arthritis (PsA).
Key findings:
- 21.7% of patients required ≥4 biologic/targeted synthetic DMARDs.
- Female patients and those with depression were more likely to be recalcitrant.
- No… https://t.co/I9YYoRnLwh https://t.co/VtnPceVLOZ
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Mental health, sex, and comorbidities are key factors in determining recalcitrant psoriatic arthritis (PsA).
Key findings:
- 21.7% of patients required ≥4 biologic/targeted synthetic DMARDs.
- Female patients and those with depression were more likely to be recalcitrant.
- No… https://t.co/I9YYoRnLwh https://t.co/VtnPceVLOZ
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
ANA neg, but ENA pos
should we care about that result?
PPV 5.5% here
(similar to 6% prev @EricFMorand: https://t.co/Hyaued3rw2)
and how many really needed the serology? Anxiety?
Surely pos ENA w neg ANA might be more hassle than help. So what to do?⬇️
#ACR24 ABST1930 @RheumNow https://t.co/rE7RmgOGey
David Liew drdavidliew ( View Tweet)
ANA neg, but ENA pos
should we care about that result?
PPV 5.5% here
(similar to 6% prev @EricFMorand: https://t.co/Hyaued3rw2)
and how many really needed the serology? Anxiety?
Surely pos ENA w neg ANA might be more hassle than help. So what to do?⬇️
#ACR24 ABST1930 @RheumNow https://t.co/rE7RmgOGey
David Liew drdavidliew ( View Tweet)
Would be helpful for us (and pts) to better understand rimmunotherapy agent specific risk on subsequent GCA/PMR
AFTRER propensity matching of >7k pt on combo nivolumab/ipilimumab compared to pembrolizumab:
- PMR RR 3.8x N/I vs. P
- no diff in GCA risk
@RheumNow #ACR24 https://t.co/IF4Gh7Cumd
Brian Jaros, MD Dr_Brian_MD ( View Tweet)